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Abstract
The MAP kinase pathway has been shown to be active in many growth factor signaling systems, including that of prolactin
(PRL). In our studies, the main objective was to examine the possible involvement of MEK kinases (Map/Erk kinase kinases)
in PRL-stimulated mitogenic and lactogenic processes. We used the MEK kinase inhibitor PD 098059 to block MEK kinase
activation in the Nb2 cell line and mammary gland explants derived from 12- to 14-day pregnancy mice. PD 098059
attenuated PRL-induced Nb2 cell mitogenesis at 10 WM and a maximum inhibition was observed at 100 WM. In cultured
mammary tissues, PD 098059 at 100 WM had no effect on the PRL stimulation of lipid, casein and lactose synthesis and
iodide uptake. Further, the growth-inhibitory effect of PD 098059 on Nb2 cells was ameliorated when the drug was removed
from the culture medium, indicating that PD 098059 acts in a reversible manner. When MEK1 was immunoprecipitated from
PD 098059 and/or PRL treated Nb2 cells, PRL-stimulated MEK1 kinase activity was directly inhibited by PD 098059 at
concentrations employed in the culture experiments. PRL has no effect on the tyrosyl phosphorylation of MAP kinases in
cultured mammary tissues derived from pregnant mice, whereas earlier we found that PRL stimulates the tyrosyl
phosphorylation of all four MAP kinases in Nb2 cells. The results suggest that the MAP kinase pathway plays an important
role in the PRL stimulation of Nb2 cell mitogenesis but is not involved in the PRL stimulation of milk product
synthesis. ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
In recent years, multiple signaling pathways have
been shown to be involved in prolactin (PRL) regu-
lation of milk product synthesis in the mammary
gland and mitogenesis in Nb2 and mammary cells.
These pathways include the synthesis of polyamines
and prostaglandins [24], as well as the activation
protein kinase C via the phosphatidyl inositol path-
way [1^4]. The MAP kinase pathway has been shown
to play an important role in many growth factor
signaling systems, including that of PRL in its mito-
genic e¡ect on Nb2 cells [5,6] and cultured mammary
cells [7].
In order to study further the PRL signaling path-
ways, two primary model systems were employed:
Nb2 cells in which the mitogenic e¡ect of PRL is
expressed, and the mouse mammary gland explant
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system in which the lactogenic e¡ects of PRL are
expressed. The Nb2 cell line, the only cell line known
to express the intermediate form of the PRL receptor
[8], is dependent on lactogenic hormone stimulation
for continuous progression through the cell cycle [9].
To date, several kinases that are activated in re-
sponse to PRL in Nb2 cells have been identi¢ed;
these include protein kinase C [1^4], RAF1 [10],
JAK2 kinase [11^13], MAP kinase [14], P21ras [6]
and the S6 kinase family [15,16]. Further studies in-
dicate that MAP kinase may represent an integration
point of signal transduction where serine/threonine
kinase pathways and tyrosine kinase pathway are
merged [17]. The goal of the present studies was to
characterize the upstream entities in the PRL regu-
lation of the MAP kinases in the Nb2 cells, and to
assess the role of the MAP kinase pathway in the
di¡erentiative actions of PRL in the mammary
gland.
PD 098059 is a speci¢c, noncompetitive MEK in-
hibitor [18]. It completely blocks NGF-induced neu-
rite formation in PC-12 cells [19], the IGF-1 acti-
vated mitogen protein kinase pathway [20] by
inhibiting MAP kinase activity, and many other
MAP kinase signaling systems. PD 098059 was thus
employed to assess whether MAP kinase activation is
required for both PRL stimulation of mitogenesis in
Nb2 cells and milk product synthesis in cultured
mammary cells.
2. Materials and methods
2.1. Materials
Stocks of Nb2 cells were provided by C.T. Beer
(Cancer Control Agency, Vancouver, B.C., Canada).
Midpregnant (10^14 days of pregnancy) Swiss^Web-
ster mice were purchased from Harlan Laboratories
(Indianapolis, IN). Ovine PRL (oPRL) (NIH-P-S-17)
was a gift from NIDDK. Other materials were pur-
chased from the following sources: cortisol from
Charles P¢zer (New York, NY); Medium 199 Earle’s
salts, Hanks’ balanced salt solution, Fischer’s me-
dium, AIM-V medium, fetal calf serum, and horse
serum from Gibco Laboratories (Grand Island,
NY); porcine insulin, penicillin, and streptomycin
from Eli Lilly (Indianapolis, IN); [4,5-3H]leucine
(53 Ci/mM), [1-14C]acetate (59 mM/mmol), thymi-
dine, [methyl-3H]glucose (20 Ci/mmol), and [5,6-
3H]glucose (66.6 Ci/mmol) from New England Nu-
clear (Boston, MA); cellulose TLC plates and 2-pro-
pranolol from Fischer Chemical (Waltham, MA);
125I and enhanced chemiluminescence reagents from
Amersham (Arlington Heights, IL); PVDF mem-
branes from Scheicher and Schuell (Keene, NH);
and PD 098059 from RBI (Natick, MA).
2.2. Nb2 cell culture
The PRL-dependent Nb2 cell line was grown in
Fischer’s medium supplemented with 10% fetal calf
serum and 10% horse serum, 1.0U1034M 2-mercap-
toethanol, 100 IU/l penicillin, and 100 Wg/ml strepto-
mycin, as previously described. Incubation for 24 h
in serum-free Fischer’s media e¡ectively arrests
growth at the G0/G1 phase of the cell cycle. Once
serum depletion was complete, cells were harvested
and treated with oPRL.
2.3. Nb2 mitogenesis assay
Nb2 cells arrested at G0/G1 in the cell cycle were
resuspended in serum-free AIM-V (stationary media)
at 1.3U105 cells/ml. Cell aliquots of 800 Wl were then
distributed into 24-well plates, and increasing con-
centrations of PD 098059 in 100-Wl quantities were
added. Next, either 500 pg/ml oPRL or ‘stationary
media’ were added in 100-Wl aliquots to bring the
total volume of each sample to 1 ml. Incubation of
cells was carried out for 72 h, after which cell num-
ber was determined using a Coulter counter. For
[3H]thymidine incorporation, Nb2 cells were cultured
in 96-well plates initially with 2000 Nb2 cells in 200 Wl
AIM-V medium. Cells were cultured for 72 h and
1 WCi of [3H]thymidine was added during ¢nal
16 h. [3H]Thymidine incorporation into DNA was
measured by quantitatively collecting the cells with
a 96-well plate cell harvester (Tomac). The labeled
DNA from lysed cells was collected on ¢ber mats
which were counted employing a Wallac Beta-plate
counter [27].
2.4. Mouse mammary gland explant preparation
Mammary gland explants were prepared as previ-
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ously described from mice that were pregnant 12^14
days [22]. Mice were killed by cervical dislocation;
mammary glands were removed and placed in
Hank’s balanced salt solution. Explants (3^6 mg
each) from each of 8^10 animals were prepared and
placed on siliconized lens paper in 60-mm petri
dishes containing 6 ml of Medium 199 Earle’s salts
with 1 Wg/ml insulin and 1037 M cortisol. Next, tis-
sues were incubated for 24 h at 37‡C under humidi-
¢ed 95% air/5% CO2 atmosphere prior to experimen-
tation. All studies involving the preparation of
mouse mammary gland explants were performed in
compliance with the regulations of the Animal Care
and Use Committee of Wayne State University.
2.5. Mouse mammary gland bioassays
After an initial 24-h incubation, M 199 media was
aspirated from tissues and replaced with 4 ml of
fresh M 199 containing 100 WM PD 098059 and/or
1 Wg/ml PRL. Incubations were then continued for
an additional 24 h, after which the incorporation of
radioactive precursors into macromolecules was de-
termined. In experiments involving the rate of lactose
synthesis, mammary gland tissues were exposed to
0.5 WCi/ml [5,6-3H]glucose for the last 2 h of incuba-
tion in order to pulse label lactose. Labeled lactose
was separated from labeled glucose on TLC plates
and the radioactivity quantitated. For experiments in
which the rate of casein synthesis was determined,
[3H]leucine (0.5 WCi/ml) was added to culture me-
dium for the ¢nal 2 h of incubation. Quantities of
[3H]leucine incorporated into the casein-rich phos-
phoprotein fraction were determined in a protein
fraction isoelectrically precipitated at pH 4.6. In ex-
periments determining the rate of lipid synthesis, tis-
sues were exposed to [14C]acetate (0.5 WCi/ml) for the
last 2 h of incubation. Tissues were then weighed,
homogenized in 400 Wl of distilled water, and the
lipids extracted by the method of Bligh and Dyer
[28]. Radioactivity in the organic layer was then
quantitated. Results are expressed as disintegrations
per mg wet tissue weight. Finally, in experiments
determining the rate of iodide uptake, tissues were
transferred to vessels containing 125I (0.25 WCi/ml,
0.3 ng/ml iodide) for the last 4 h of incubation. Tis-
sues were then weighed and the amount of 125I ac-
cumulated was quantitated (dpm/mg tissue weight).
2.6. Nb2 cell and mammary gland explant lysate
preparations
Both G1-arrested Nb2 cells (1U106/ml) and prein-
cubated mouse mammary gland explants were
treated with or without 25 WM PD 098059 and in-
cubated for 24 h as described above. Samples were
then washed twice with ice-cold phosphate-bu¡ered
saline (PBS)^orthovanadate (1 mM). Nb2 cells were
resuspended, at 4‡C, in lysis bu¡er (2.0U107 cells/ml)
containing 2% NP40, 10 mM Tris, 50 mM NaCl,
30 mM sodium pyrophosphate, 2.5 mM EDTA,
1 mM orthovanadate, 1 mM phenylmethylsulfonyl
£uoride, 10 Wg/ml aprotinin and 10 Wg/ml leupeptin,
at pH 7.6. Mouse mammary gland explants were
weighed, added to lysis bu¡er (1:2, w/v) and dis-
rupted with a ground-glass homogenizer. After
30 min on a rocking platform, lysates were centri-
fuged (100 000Ug) for 30 min at 4‡C. The resulting
supernatants were used for immunoprecipitation and
subsequently quantitated for total levels of MEK or
MAP kinases in the prepared samples.
2.7. Immunoprecipitation and immunoblotting
After PRL and PD 098059 treatment, Nb2 cells
(1U106/ml) were washed through 4Uvolume of
PBS^orthovanadate (1 mM) at 4‡C by centrifugation
(200Ug, 3 min) and resuspended in lysis bu¡er
(2U107/ml). The cleared lysate (1 ml), containing
3.7 mg protein/ml, was immunoprecipitated (over-
night at 2‡C) with either agarose-conjugated anti-
phosphotyrosine (UBI 16-101; 25 Wg monoclonal
Ab/ml lysate), or anti-rat MAP kinase (UBI 06-
182; 1 Wg/ml) followed by addition of 50 Wl protein
A Sepharose beads (Pharmacia 17-0974-04). Proteins
were solubilized in sodium dodecyl sulfate (SDS)^
Laemmli sample bu¡er, separated by SDS^poly-
acrylamide gel electrophoresis (PAGE) (8^20%
linear gradient) under reducing conditions and
transferred to PVDF membranes (Schleicher and
Schuell). Membranes were probed with horseradish
peroxidase (HRP)-conjugated anti-phosphotyrosine
(UBI 16-105; 20 ml at 1 Wg/ml) for 2 h or with
anti-MAP kinase (UBI 06-182; 20 ml at 1 Wg/ml)
for 2 h followed by treatment with anti-rat IgG
HRP conjugate (Amersham NA934; 25 ml at
1:5000 dilution for 1.5 min). Detection was accom-
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plished by incubation with enhanced chemilumines-
cence reagents (Amersham) and exposure to X-ray
¢lm. MEK1 kinase activity was assessed according
to the UBI protocol. Brie£y, the immunoprecipitated
MEK1 enzyme was used to phosphorylate and acti-
vate recombinant p42 MAP kinase. Activated MAP
kinase and [Q-32P]adenosine triphosphate (ATP) were
used to phosphorylate a speci¢c substrate, myelin
basic protein. The phosphorylated substrates were
separated from the residual [Q-32P]ATP by di¡erential
binding to p81 phosphocellulose paper. The radio-
activity bound to the paper was quantitated in a
liquid scintillation counter.
Statistical comparisons were made with Student’s
t-test for comparing two means, or with an analysis
of variance followed by Sche¡e’s test for multiple
comparisons. Signi¢cant di¡erences (P6 0.05) are in-
dicated by asterisks in the ¢gures.
3. Results
In initial experiments, the e¡ect of increasing con-
centrations of PD 098059 on PRL-induced mitogen-
esis was determined in G1-arrested Nb2 cells. Fig. 1
shows that after 72 h of culture, PRL-stimulated
proliferation is reduced by 50% when PD 098059
levels exceed 10 WM; maximum inhibition is ob-
served at 100 WM. Control cell numbers are not sig-
ni¢cantly a¡ected by treatment with PD 098059 at
any of the concentrations employed. DMSO, the sol-
vent for PD 098059, was maintained below 0.05%
and had no e¡ect on cell number (data not shown).
Thus, these studies support a physiological role for
MEK kinase in the PRL stimulation of mitogenesis
in Nb2 cells since the MEK-speci¢c inhibitor sup-
pressed the PRL response.
To characterize the e¡ect of PD 098059 on Nb2
Fig. 1. The e¡ect of PD 098059 on PRL-stimulated Nb2 cell mitogenesis. Nb2 cells (1.3U105) arrested in G1 phase were treated with
increasing concentrations of PD 098059 in the presence or absence of 500 pg/ml oPRL. After incubation for 72 h, cell population was
determined. b, Control; F, PRL-treated cells. Values represent the mean þ S.E.M. of six observations.
Table 1
E¡ect of PD 098059 on mitogenesis in Nb2 cells
Cell number (U103)
Day 0 Day 3
Control 50 633 þ 5.6
PRL 500 991 þ 2.5*
PRL+PD 500 672 þ 5.4
Nb2 cells were washed three times with AIM-V medium and
cultured for 24 h with 5 ng/ml PRL in the presence or absence
100 WM PD 098059 in 10 ml AIM-V medium. Cell numbers
was then determined. The results represent mean þ S.E.M. of
three observations.
*P6 0.01.
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cell mitogenesis, several studies were carried out. Ta-
bles 1 and 2 contain the results of reversibility stud-
ies. Table 1 shows the 1-day PRL and/or PD 098059
e¡ect on Nb2 cell number. By itself, PRL doubled
Nb2 cell number whereas in the presence of PD
098059 (100 WM), PRL-stimulated Nb2 cell mitogen-
esis is inhibited. Table 2 shows that a 24-h treatment
of Nb2 cells with PD 098059 has no e¡ect on the
subsequent mitogenic response to PRL during a fur-
ther 72 h of culture. The PD 098059 inhibition is
thus completely reversible. In order to further study
the e¡ects of PD 098059 on Nb2 cell mitogenesis, a
[3H]thymidine incorporation experiment was carried
out (Fig. 2). After a 72-h culture, PD 098059 signi¢-
cantly inhibited PRL-stimulated [3H]thymidine in-
corporation in a concentration^response manner.
Concentrations of PD 098059 above 20 WM abol-
ished the PRL response.
To establish the e⁄cacy of PD 098059 in inhibiting
MEK activity, we examined the ability of this com-
pound to inhibit PRL-stimulated MEK1 kinase ac-
tivity. Fig. 3 shows that PD 098059 completely pre-
vents the PRL stimulation of MEK1 activity.
To further con¢rm that PD 098059 speci¢cally
blocks the PRL activation of MAP kinases, we ex-
amined the PD 098059 e¡ect on the tyrosine phos-
phorylation of the MAP kinase enzymes. Nb2 cells
Fig. 2. E¡ect on PD 098059 on DNA synthesis induced by PRL in Nb2 cells. Nb2 cells (2000/well) were treated with increasing con-
centration of PD 098059 in the presence or absence of 500 pg/ml PRL for 72 h and 1 WCi of [3H]thymidine was added during the
¢nal 16 h. The labeled DNA from lysed cells is collected on ¢ber mats which were determined by a Wallac Beta-plate counter.
E, without PRL; F, PRL-treated cells. Values represent the mean þ S.E.M. for six observations. The signi¢cance value represents com-
parison with the PRL-treated cells only (*P6 0.05; **P6 0.01).
Table 2
E¡ect of PD 098059 removal on mitogenesis in Nb2 cells
Cell number (U103)
Day 0 Day 3
Control^Control 100 83 þ 1.8
PRL^PRL 100 820 þ 2.4*
PRL+PD^PRL 100 871 þ 2.2*
PRL+PD^Control 100 92 þ 1.4
Nb2 cells (1U105) were cultured for 24 h as in Table 1, washed
with AIM-V, and then subcultured in 24-well plates for the
next 72 h with or without 500 pg/ml PRL. The cell number
was then determined. The results represent the mean þ S.E.M.
of six observations.
*P6 0.01.
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were treated with or without PD 098059 for 90 min
as described above, followed by addition of 50 ng/ml
oPRL for 10 min. Cells were lysed, and lysates were
precipitated with either anti-MAP kinase R2 or anti-
phosphotyrosine antibodies. After SDS^PAGE and
transfer to PVDF membranes, the blots were probed
with an anti-phosphotyrosine antibody (Fig. 4A).
PRL clearly increases the tyrosyl phosphorylation
of P44 MAP and P42 MAP (lane G) whereas inhi-
bition is observed in the presence of PD 098059
(lane H). Fig. 4B displays the identical blot as Fig.
4A except it is probed with anti-MAP kinase anti-
body; the consistent amount of MAP kinases in each
lane is apparent. In Fig. 4B, where anti-phospho-
tyrosine immunoprecipitates were probed with anti-
MAP kinase antiserum, proteins from PRL-stimu-
lated Nb2 cell lysates (lane C) exhibit an increase
in anti-MAP kinase antibody binding, thus demon-
strating that PRL increases MAP kinase tyrosine
phosphorylation. This PRL-induced tyrosyl phos-
phorylation is totally inhibited by pretreatment
with PD 098059 (lane D). Fig. 4C shows PRL has
no e¡ect on MAP kinase tyrosyl phosphorylation in
lysates derived from mouse mammary gland tissues.
The potential role of MAP kinase activation in the
stimulation of milk product synthesis was examined
in cultured mouse mammary tissues. Fig. 5 shows
that PD 098059 has no e¡ect on PRL-stimulated
glucose incorporation into lactose (Fig. 5A) or ace-
tate incorporation into lipids (Fig. 5B). As seen in
Fig. 6, PD 098059 at 100 WM also has no e¡ect on
the PRL stimulation of iodide uptake (Fig. 6A) or
casein synthesis (Fig. 6B) in cultured mammary tis-
sues. These studies clearly show that PD 098059, a
speci¢c MEK kinase inhibitor, has no e¡ect on the
PRL stimulation of the synthesis of several milk
products, whereas it completely abolishes the mito-
genic e¡ect of PRL in Nb2 cells.
4. Discussion
Several important issues regarding PRL signaling
Fig. 4. The e¡ect of PD 098059 on PRL-induced tyrosine phos-
phorylation of MAP kinase in Nb2 cells. G1-arrested Nb2 cells
(1U106/ml) were incubated for 90 min in the absence (lanes A,
C, E and G) or presence (lanes B, D, F and H) of 100 WM PD
098059; 50 ng/ml oPRL was present for the ¢nal 10 min (lanes
C, D, G and H). Total cell lysate preparations were immuno-
precipitated with either anti-phosphotyrosine (lanes A^D) or
anti-MAP kinase R2 (lanes E^H). The samples were separated
on 8^20% SDS^PAGE. The blots were probed with anti-phos-
photyrosine (A) or anti-MAP kinase antibodies (B). (C) The
time course of PRL (1 Wg/ml) treatment of mouse mammary
gland tissues. Total tissue lysate was separated by 8^20% SDS^
PAGE and blotted with anti-phosphotyrosine. This blot is rep-
resentative of these replicate experiments.
Fig. 3. The e¡ect of PD 098059 on MEK1 kinase activation in
Nb2 cells. G1-arrested Nb2 cells (1U106/ml) were incubated in
the absence or presence of 100 WM PD 098059 for 90 min; 50
ng/ml oPRL was added for the ¢nal 10 min. Total cell lysate
preparations were immunoprecipitated with anti-MEK1 kinase
antibody. MEK1 kinase assay was carried out according to
methods provided by UBI. *P6 0.01.
BBAMCR 14388 11-11-98
T.X. Yu, J.A. Rillema / Biochimica et Biophysica Acta 1448 (1998) 126^134 131
pathways are addressed in these studies. First, PRL
was shown to stimulate MEK enzymatic activity in
Nb2 cells. Since MEK is an upstream activator of the
MAP kinases, the PRL stimulation of MEK is likely
causally related to the PRL stimulation of the MAP
kinases. These observations are consistent with ear-
lier studies [7] where PRL was reported to stimulate
MEK and MAP kinase activities in cultured neoplas-
tic mammary cells. In further studies we found that
the MEK inhibitor PD 098059 abolished the PRL
stimulation of mitogenesis and [3H]thymidine incor-
poration in Nb2 cells, while at the same time this
drug abolished the PRL e¡ects on MEK and MAP
kinase enzymatic activities. The e⁄cacy of the PD
098059 inhibition of MEK was clearly established.
In addition, the PD 098059 inhibition of the PRL
stimulation of mitogenesis in the Nb2 cells was
shown to be completely reversible, thus suggesting
that the PD 098059 does not express its e¡ect via a
nonspeci¢c cytotoxic e¡ect on the cells. These studies
thus clearly establish that the MEK^MAP kinase
pathway is one of the integral signaling pathways
involved in the PRL stimulation of mitogenesis in
Nb2 cells. PD 098059 has been used in several earlier
studies to study the involvement of MEK activation
in the stimulation of mitogenesis in other cell systems
[18,19,23,24].
Another important observation from these
studies is that the di¡erentiative e¡ects of PRL on
lactational processes in cultured mammary tissues
[1^4,21,25,26] do not appear to involve the MEK^
MAP kinase pathway. The MEK inhibitor PD
098059, at concentrations which e¡ectively inhibited
MEK activity, had no in£uence on the PRL e¡ects
Fig. 5. PRL-stimulated lactose and lipid synthesis are insensitive to PD 098059. PRL (1 Wg/ml) stimulation of [3H]glucose incorpora-
tion into lactose (A) and [14C]acetate incorporation into lipids (B) were determined in mouse mammary tissues following pretreatment
(1 h) with (solid bars) and without (open bars) 100 WM PD 098059. Results represent the means þ S.E.M. of six observations.
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on iodide transport, casein synthesis, lactose synthe-
sis or lipid synthesis. In addition, PRL had no e¡ect
on the tyrosyl phosphorylation of the MAP kinases
in the cultured mammary tissues. This contrasts with
the mitogenic e¡ects of PRL in Nb2 cells and cul-
tured neoplastic mammary cells, where the MEK^
MAP kinase pathway is clearly involved in the
PRL signaling pathway.
In a number of earlier studies [26], several com-
mon signaling pathways have been shown to be in-
volved in the PRL stimulation of mitogenesis and
milk product synthesis. These include the polyamine,
prostaglandin, phosphatidylinositol^protein kinase C
and phosphatidylinositol 3-kinase pathways. The
present studies clearly suggest that the MEK^MAP
kinase pathway is speci¢cally involved only in the
PRL stimulation of mitogenesis, but not in the lacta-
tional di¡erentiative PRL functions.
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